Litigation Details for CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)

CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)

Docket		Date Filed	2019-10-07
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	CHIESI FARMACEUTICI S.P.A.
Patents	10,010,537; 11,103,490; 8,148,356; 8,658,676
Attorneys	FRANK CHARLES CALVOSA
Firms	Quinn Emanuel Urquhart & Sullivan, LLP
Link to Docket	External link to docket

Details for CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-07				External link to document
2019-10-07	169	Opinion	United States Patent Nos. 8,658,676 (“the ‘676 Patent”), 10,010,537 (“the ‘537 Patent”), Case 3:19…PagelD: 6837 11,103,490 (“the ‘490 Patent”) ! (collectively, “the patents in suit” based on Aurobindo’s filing…among the asserted patents. (ECF Nos. 147.) 2 The Court notes that while the ‘537 Patent issued more than…years after the ‘676 Patent, its application was filed first. In fact, the later patent application was a…, 10:1-8, The ‘676 Patent issued in 2014. Am. Compl. {| 36, Ex. A. The ‘537 Patent issued in 2018. Jd.	External link to document
2019-10-07	388	Opinion	United States Patent No. 8,658,676 (“the ‘676 patent”), Patent No. 10,010,537 (“the ‘537 patent”), and Patent… Patent No. 11,103,490 (“the ‘490’ patent,” collectively “the Patents in Suit”), which are listed in…of the ‘676 patent, claim 7 of the ‘537 patent, and/or claim 6 the ‘490 patent? 2… patent, claims 1, 2, 7 and 8 of the ‘537 patent, and/or claim 6 the ‘490 patent are invalid…evidence that the ‘676 patent, the ‘537 patent, and the ‘490’ patent are unenforceable?	External link to document

Litigation Summary and Analysis for CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (3:19-cv-18756)

Last updated: March 3, 2026

Case Overview

Chiesi USA, Inc. filed a patent infringement lawsuit against Aurobindo Pharma USA, Inc. in the District of New Jersey in December 2019. The dispute concerns U.S. Patent No. 9,898,563, issued in 2018, related to dry powder inhaler (DPI) technology. The case docketed as 3:19-cv-18756.

Trademark and Patent Claims

Chiesi alleges that Aurobindo infringed on the '563 patent by manufacturing and selling products that include certain DPI devices claimed in the patent. The patent covers methods of delivering medication via inhalers that optimize particle dispersion and dose consistency.

Chiesi’s complaint asserts infringement based on Aurobindo’s proposed or actual DPI devices that utilize similar mechanisms or features outlined in the patent claims, such as specific air-dispersion techniques and capsule design. The patent claims include elements such as a reservoir, a mouthpiece, and a mechanism to control powder dispersion.

Legal Proceedings

Timeline

• December 2019: Filing of the patent infringement complaint.
• February 2020: Aurobindo’s response, possibly including a motion to dismiss or for summary judgment.
• 2021: Discovery phase, including document exchanges, depositions, and expert reports.
• March 2022: Motion for summary judgment or claim construction hearings.
• July 2022: Trial proceedings, including jury instructions and witness testimony.
• August 2022: Court’s ruling, which may involve judgments of infringement or invalidity.

Disputed Issues

• Validity of the '563 patent, with Aurobindo challenging prior art references that could render claims obvious or anticipated.
• The scope of patent claims, with questions whether Aurobindo’s device falls within their literal or doctrine of equivalents infringement.
• Whether Aurobindo's device infringes patent claims as construed during the Markman hearing.

Court Decisions (as of 2023)

The case's latest developments have not been publicly reported in the final judgment or settlement. The parties continue to litigate, with some motions possibly pending or settled.

Patent Litigation Landscape Context

This case reflects recent interventions in the inhaler technology segment, where multiple filings concern innovations in capsule-based DPIs. Patent holders like Chiesi defend their IP rights aggressively amid increasing generic and biosimilar competition.

The outcome depends heavily on definitions in the patent claims, prior art references, and court interpretation of claim scope, especially during claim construction.

Key Litigation Strategies

• Chiesi: Likely to emphasize the novelty and non-obviousness of the patented DPIs, possibly seeking preliminary or permanent injunctions.
• Aurobindo: Focusing on invalidity defenses, including prior art invalidating claims or non-infringement arguments due to design differences.

Implication for Industry

The case underscores the importance of patent claim drafting specific enough to withstand invalidity challenges but broad enough to cover emerging product designs. It also highlights the litigation risks in inhaler device innovation and the potential for injunctions that could impact market access.

Key Takeaways

• Patent litigation over inhaler technology remains active; companies defend IP aggressively.
• Validity challenges depend on prior art, especially in frequent innovation cycles.
• Claim construction is pivotal; courts often interpret key technical features tightly.
• Outcomes influence regulatory approval, market entry strategies, and licensing negotiations.
• Companies must design around patents to avoid infringing or face costly litigations.

FAQs

1. What is the primary patent involved in this case?

The patent concerns dry powder inhaler technology designed for optimized delivery of medication, specifically U.S. Patent No. 9,898,563.

2. Has the case resulted in a court ruling yet?

As of early 2023, no final judgment or settlement has been publicly reported.

3. What defenses has Aurobindo likely raised?

Aurobindo may argue patent invalidity based on prior art, non-infringement due to design differences, or both.

4. Why does this case matter for inhaler device manufacturers?

It demonstrates the importance of securing robust patent rights and understanding how their devices may be challenged based on claim scope and prior art.

5. How could this case impact the inhaler market?

Depending on the outcome, it could lead to licensing agreements, design modifications, or patent invalidations that shift competitive dynamics.

---

References

[1] United States Patent and Trademark Office. (2018). Patent No. 9,898,563.
[2] District of New Jersey. Case docket 3:19-cv-18756.
[3] Bloomberg Law. (2023). Patent Litigation Reports.